Pien Huang
Pien Huang is a health reporter on the Science desk. She was NPR's first Reflect America Fellow, working with shows, desks and podcasts to bring more diverse voices to air and online.
She's a former producer for WBUR/NPR's On Point and was a 2018 Environmental Reporting Fellow with The GroundTruth Project at WCAI in Cape Cod, covering the human impact on climate change. As a freelance audio and digital reporter, Huang's stories on the environment, arts and culture have been featured on NPR, the BBC and PRI's The World.
Huang's experiences span categories and continents. She was executive producer of Data Made to Matter, a podcast from the MIT Sloan School of Management, and was also an adjunct instructor in podcasting and audio journalism at Northeastern University. She worked as a project manager for public artist Ralph Helmick to help plan and execute The Founder's Memorial in Abu Dhabi and with Stoltze Design to tell visual stories through graphic design. Huang has traveled with scientists looking for signs of environmental change in Cameroon's frogs, in Panama's plants and in the ocean water off the ice edge of Antarctica. She has a degree in environmental science and public policy from Harvard.
-
So far the government has distributed nearly 400,000 doses of Evusheld, a new drug that protects against COVID-19. Some 7 million Americans could benefit from the drug right away. -
When he came into office, Biden launched an ambitious seven-point plan for defeating the virus. Here's how experts score his results.
-
Those who contracted COVID-19 can end their isolation after five days while continuing to wear a well-fitting mask for an additional five days, according to the agency.
-
Cutting the isolation for positive cases to five days could lead to more infections if people don't take masking seriously. A testing requirement would have made the policy safer, experts say.
-
The FDA is considering new pills that could treat people in early stages of COVID. Here's what to know about how they work, how effective they are and the impact they could make on the pandemic.
-
The investment is a response to an ongoing national shortage and follows a $2 billion investment in September to supply rapid tests to community health centers, food banks and schools.
-
Scientists are still studying whether the deworming medicine could have any effect on COVID-19. But the frenzy over the drug has far more to do with politics than science. Here's how that happened.
-
If all goes to plan, Americans who got Pfizer or Moderna shots can get a third dose eight months after their last jab. Here's why health officials think you'll need one.
-
Some public health experts are also parents of little kids, and have to strategize to keep those too young to be vaccinated safe from getting or spreading the delta variant. Here are their tips.
-
The state has one of the lowest vaccination rates in the U.S. And this weekend, 80,000 doses will expire because of lack of demand. The campaign is on to get people to sign up.
